Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T16:44:26.193Z.
Calculation as of: 2026-10-06T16:44:26.193Z.
Quote observation: 2026-10-06T16:40:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 833b8a33f5e3aa548e06775940c7a83493d9a3083fc648ecb3f8ecd80d633b38
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$243.06M
Price/OCF Ratio
N/A
TTM Avg
252.82
3Y Avg
252.82
5Y Avg
155.13
Market Cap
$242.57M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$242.23M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$242.35M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$241.80M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quantum-Si incorporated (QSI) | $246.29M | N/A | N/A | N/A | N/A |
| Q32 Bio Inc. (QTTB)vs › | $246.15M | N/A | 8.05 | 8.05 | 8.05 |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.06M | N/A | 252.82 | 252.82 | 155.13 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $242.57M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $242.23M | N/A | N/A | N/A | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $242.35M | N/A | N/A | N/A | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $241.80M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $241.02M | N/A | N/A | N/A | N/A |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $249.78M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $239.07M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
